It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- A clinical-stage oncology company specialized in developing the next-generation T cell-based immunotherapies for treating blood cancers and solid tumors
- Leverages its MultiTAA tech to develop novel cell-therapies
- Lead program (MT-401)= in P2 for acute myeloid leukemia (AML)
- MRKR’s tech is also being tested in several early-stage studies by the Baylor College of Medicine